Abstract:
Introduction. The use of antibacterials has become increasingly
strained due to increased rates of resistance & with less development of
new agents. As a result, multi-, extensively-, and pan-drug resistant
bacterial strains are now frequently encountered.
Purpose. To highlight recently developed antibacterial medicines and
their role in clinical practice.
results. 11 new antibiotics that have been approved since 2017, New
drug Pretomanid is an antimycobacterial indicated, as part of a
combination regimen(fig-1).
Cefiderocol for the treatment of urinary tract infections and acute
pyelonephritis. Also as first-line therapy for Infection-related
Ventilator-Associated Complications, Hospital-acquired pneumonia &
Ventilator-associated pneumonia (fig 2). Ceftazidime-avibactam
licensed for carbapenemase producers(fig 3). In adults specifically
addressing the use of fidaxomicin and bezlotoxumab for the treatment
of C. difficile infection (fig 4).
Conclusions. New antibacterial agents are mainly derivatives
of existing classes. There is a significant need for novel
antibacterial drugs and research.
